CAR-T Meeting 2022 | Dealing with the rapid progress in CAR-T therapies
The field of chimeric antigen receptor T-cell (CAR-T) therapy for hematological malignancies is rapidly evolving, with an increasing number of products, indications, and candidates for CAR-T therapy. In this video, Stephan Mielke, MD, PhD, Karolinska Institute, Solna, Sweden, talks on dealing with the complexity arising from an increased number of options for CAR-T therapy in the clinic. As new CAR-T therapies are moved from clinical trials to clinical practice, it will be important to optimize treatment using lessons from real-life experiences. In addition, CAR-T therapies are currently being evaluated in earlier lines of treatment for hematological malignancies and are also being developed for solid tumors, which will significantly increase the number of candidates for CAR-T therapy. This interview took place at the EBMT-EHA 4th European CAR T-cell Meeting which was held virtually in 2022.
Disclosures
Celgene/BMS, Novartis, DNA Prime SA: Speakers bureau (via institution)
Gilead/KITE: Other: Travel support, Expert panel (via institution)
Miltenyi, Immunicum: Other: Data safety monitoring board (via institution)
